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Introduction
Breast cancer encompasses a heterogeneous group of
neoplasms, characterised by distinct morphological
appearances, genetic alterations and biological behaviours.
Comprehension of the molecular and genetic events affect-
ing breast cancer development not only helps in address-
ing complex and relevant biological questions but also
helps in gaining insights into the complexity of the disease.
In breast cancer, a frequent mechanism of oncogene acti-
vation is gene amplification. Some of the most frequently
amplified genes in these tumours are her-2/neu, c-myc and
the genes encoding cyclin D1 and topoisomerase II-α.
Recently, Schlotter and colleagues [1] provided new data
about the role of c-myc and her-2/neu oncogenes as prog-
nostic factors in breast cancer. In brief, the authors evalu-
ated the amplification of c-myc and her-2/neu in a cohort of
181 patients with node-negative breast cancer by means
of double differential polymerase chain reaction (ddPCR).
c-myc and her-2/neu were amplified in 21.5% and 30.4%
of the cases, respectively. Interestingly, it was shown by
both univariate and multivariate analysis that c-myc, but not
her-2/neu, was associated with poor disease-free survival
(DFS). The authors also demonstrated that when different
adjuvant therapies were included in the statistical analyses,
neither c-myc nor her-2/neu could predict the DFS or
overall survival (OS) in those patients who received
chemotherapy and endocrine treatment. However, c-myc
amplification was associated with shorter DFS and OS in
patients who did not receive any sort of adjuvant therapy.
The authors concluded that c-myc amplification seems to
be a strong prognostic marker that might predict early
recurrence for node-negative breast cancer patients.
How novel?
Associations between oncogene amplifications and prog-
nosis of breast cancer patients have been described for
more than 20 years. In 1987, Slamon and colleagues [2]
described the association between her-2/neu amplifica-
tion and DFS and OS of breast cancer patients. Since
then, various studies have been published, most of them
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Abstract
The predictive and prognostic implication of oncogene amplification in breast cancer has received
great attention in the past two decades. her-2/neu and c-myc are two oncogenes that are frequently
amplified and overexpressed in breast carcinomas. Despite the extensive data on these oncogenes,
their prognostic and predictive impact on breast cancer patients remains controversial. Schlotter and
colleagues have recently suggested that c-myc, and not her-2/neu, could predict the recurrence and
mortality of patients with node-negative breast carcinomas. Regardless of the promising results,
caution should be exercised in the interpretation of data from studies assessing gene amplification
without in situ analysis. We address the novelty, accuracy and clinical significance of the study by
Schlotter and colleagues.
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with conflicting results. Although it is clear that her-2/neu
amplification in breast cancer is associated with high his-
tological grade, lack of hormone receptors and a relative
or absolute resistance to endocrine therapy, the data on
the prognostic significance of her-2/neu are rather contro-
versial and still remain unsettled [3–5].
The situation is not so different for c-myc [6,7]. The rates
of c-myc amplification in breast cancer described so far
are highly variable, ranging from 1% to 94.4% ([6] and ref-
erences therein). A review of these studies has shown that
c-myc amplification is more likely to be found in tumours of
high histological grade, with positive lymph-node status
and negative progesterone-receptor status and less likely
to be observed in tumours from post-menopausal women
[6]. Apart from the study of Schlotter and colleagues [1],
all studies performed so far that have shown the indepen-
dent prognostic significance of c-myc were retrospective
[6,7]. In addition, other studies addressing the influence of
c-myc on the response for therapeutic regimens in breast
cancer are very scant.
The concept of concurrent amplification of multiple onco-
genes in breast carcinomas is not novel. Cuny and col-
leagues [8] have demonstrated the importance of
concomitant amplification of oncogenes in breast cancer:
in a large cohort of breast carcinomas, her-2/neu and
c-myc held no statistically significant association with
disease outcome, whereas the concomitant amplification
of both oncogenes proved to be associated with DFS or
OS. Taken together, the above data and the present study
show only that c-myc is a promising putative prognostic
factor that should be validated in larger and more robust
prospective studies.
How accurate?
Several studies have stressed that in situ methods are
more reliable in detecting her-2/neu and c-myc amplifica-
tion than those using molecular methods (Southern blot,
slot-blot, dot-blot and PCR) on fresh or frozen tumour
tissue macerates without the use of laser-capture
microdissection [3,5,9,10]. In the study performed by
Schlotter and colleagues (1), ddPCR was used to assess
her-2/neu and c-myc amplification. This technique was
first described for the analyses of her-2/neu amplification
by Brandt and colleagues [11] in 1995 and for c-myc
amplification by Beckmann and colleagues in 1999 [12].
Basically, in this method, DNA fragments of two different
single-copy reference genes (manganese superoxide dis-
mutase [SOD] and human β-globin [HBB]) and the target
DNA fragment (her-2/neu or c-myc) are amplified simulta-
neously in one reaction tube. The her-2/neu or c-myc PCR
product is bracketed by the SOD2 (90 base pairs) and
HBB (252 base pairs) PCR fragments. Sequences are
amplified exponentially in a thermocycler and the results
can be assessed by (1) the analysis of band intensities of
the PCR products in silver-stained polyacrylamide gels,
which expresses the average gene copy number per cell
(as described for her-2/neu), or (2) the analysis of the
products by means of standardized laser-induced capillary
electrophoresis.
Despite the claimed reliability, sensitivity and rapidity of
ddPCR for the quantification of gene dosages [11,12],
this method cannot differentiate gains of chromosome 8q
or 17q from c-myc or her-2/neu amplification, respec-
tively; nor can it address the heterogeneity of gene amplifi-
cation in a given neoplasm. c-myc amplification
heterogeneity is quite marked in different neoplastic popu-
lations of a given breast carcinoma, even in those popula-
tions microdissected from the same slide [13]. It therefore
seems reasonable that, ideally, ddPCR would require
microdissected samples composed of representative pop-
ulations of a given tumour; otherwise the sensitivity of the
method would be significantly reduced. It should be noted
that in recent years ddPCR has been replaced by real-time
PCR. Real-time PCR has proved more robust than ddPCR
and can also be performed on DNA extracted from forma-
lin-fixed paraffin-embedded tissue sections [14,15].
Several lines of evidence support the proposal that aneu-
ploidy is a very frequent event in breast carcinomas and it
seems clear that breast carcinomas of different histologi-
cal grades harbour distinct chromosomal gains and losses
as detected by in situ hybridisation and comparative
genomic hybridisation coupled with laser-capture
microdissection [16,17]. Chromosomes 8q and 17q are
among the most frequent chromosomal gains in breast
carcinomas, mainly in those of high histological grades
[17]. Interestingly, these are the chromosomal arms in
which c-myc and her-2/neu, respectively, are located. It
should be stressed that the issue on aneuploidy becomes
even more complex if the results published by Rum-
mukainen and colleagues [18] are taken into account; in
brief, these authors, using FISH (fluorescence in situ
hybridisation) with probes for chromosome 8 centromere
and c-myc, demonstrated that c-myc is strongly associ-
ated with tumour aneuploidy. Moreover, Janocko and col-
leagues [19] demonstrated that the amplification of
her-2/neu and c-myc is significantly more frequent in ane-
uploid neoplasms.
We do not dispute that the results published by Schlotter
and colleagues [1] are very promising and clearly merit
further study. However, it seems clear that their results are
not definitive because of (1) intratumoural heterogeneity,
(2) putative contamination with stromal cells (in the study
by Schlotter and colleagues it is not clear whether the
lesions were grossly or microscopically dissected, nor was
the proportion of neoplastic to stromal cells available) and
(3) the fact that the authors failed to validate their ddPCR
results with in situ analysis with cosmid probes for the
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target genes and centrosomic probes for chromosomes 8
and 17.
How significant?
As stressed above, breast carcinomas are highly hetero-
geneous, and different histological types show distinct
oncogenetic pathways [16,17,20–23]. It has been
demonstrated by in situ methods, when tumours are strat-
ified according to histological type, that lobular carcino-
mas rarely harbour her-2/neu or c-myc amplification,
whereas this event is significantly more frequent in
non-lobular breast carcinomas [19]. Also, apart from the
clinical pathological factors discussed above, some
studies have shown that c-myc amplification is associ-
ated with high histological grade, proliferation index and
apoptosis rate [6,7,11,18,24]. These findings are not sur-
prising in view of the multifunctional nature of this onco-
gene, with pivotal roles in proliferation, differentiation and
cell death [6,25]. The study by Schlotter and colleagues
[1] failed to compare c-myc amplification with the patho-
logical features of the tumours included in their series. In
addition, in multivariate analysis, the histological type,
progesterone receptor status, proliferation and apoptosis
indices were not included. Moreover, the authors failed to
evaluate critically the influence of radiotherapy on the
DFS and OS of patients with and without c-myc and
her-2/neu amplification.
Another confounding factor that seems to have been over-
looked is the presence and extension of carcinoma in situ,
which might be admixed with the invasive component and
might differ from the invasive component regarding the
amplification status of c-myc and her-2/neu. A word of
caution should be voiced because the PCR analysis of
tumour samples is often based on the assumption that all
the material present in a given ‘tumour section’ represents
tumour cells. This holds true only when the sections have
been adequately microdissected. It should be emphasised
that the inherent proclivity of PCR technology for contami-
nation problems, coupled with its very high sensitivity and
incapacity to determine whether the amplification is
present in invasive or in situ components, merits a careful
interpretation of the results of Schlotter and colleagues [1].
Conclusion
The prognostic and predictive significance of her-2/neu
and c-myc amplification in breast carcinomas still consti-
tutes one of the thorniest fields in breast cancer research.
The use of genome-wide methods, such as array-based
comparative genomic hybridisation, coupled with robust
quantitative methods for the analysis of gene amplification
[14,15] could, in the near future, allow the study of several
(if not all known) oncogenes at once. For the time being,
the study by Schlotter and colleagues [1], despite its
methodological drawbacks, has provided a promising
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